Arecor Therapeutics PLC - Asset Resilience Ratio

Latest as of December 2025: 38.62%

Arecor Therapeutics PLC (AREC) has an Asset Resilience Ratio of 38.62% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check how strategically is Arecor Therapeutics PLC's equity deployed to assess the company's strategic physical and investment asset allocation.

Liquid Assets

GBX3.13 Million

≈ $380.71 USD Cash + Short-term Investments

Total Assets

GBX8.10 Million

≈ $985.66 USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2022–2025)

This chart shows how Arecor Therapeutics PLC's Asset Resilience Ratio has changed over time. See Arecor Therapeutics PLC balance sheet quality to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Arecor Therapeutics PLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see AREC stock market capitalisation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	GBX0.00	0%
Short-term Investments	GBX3.13 Million	38.62%
Total Liquid Assets	GBX3.13 Million	38.62%

Asset Resilience Insights

Very High Liquidity: Arecor Therapeutics PLC maintains exceptional liquid asset reserves at 38.62% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

Arecor Therapeutics PLC Industry Peers by Asset Resilience Ratio

Compare Arecor Therapeutics PLC's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Ascendis Pharma AS NASDAQ:ASND	Biotechnology	0.00%
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
Spyre Therapeutics Inc. NASDAQ:SYRE	Biotechnology	84.34%
3SBio Inc F:83B	Biotechnology	10.64%
Soleno Therapeutics Inc NASDAQ:SLNO	Biotechnology	20.15%
Jiangxi Fushine Pharmaceutical Co Ltd SHE:300497	Biotechnology	0.02%
Novavax Inc NASDAQ:NVAX	Biotechnology	53.87%
BB Biotech AG SW:BION	Biotechnology	0.05%

Annual Asset Resilience Ratio for Arecor Therapeutics PLC (2022–2025)

The table below shows the annual Asset Resilience Ratio data for Arecor Therapeutics PLC.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	38.62%	GBX3.13 Million ≈ $380.71	GBX8.10 Million ≈ $985.66	+38.42pp
2024-12-31	0.21%	GBX18.00K ≈ $2.19	GBX8.72 Million ≈ $1.06K	-10.58pp
2023-12-31	10.79%	GBX1.66 Million ≈ $201.85	GBX15.38 Million ≈ $1.87K	-26.16pp
2022-12-31	36.94%	GBX8.04 Million ≈ $978.36	GBX21.77 Million ≈ $2.65K	--

pp = percentage points

About Arecor Therapeutics PLC

LSE:AREC UK Biotechnology

Market Cap

$287.12K

GBX2.36 Billion GBX

Market Cap Rank

#31017 Global

#984 in UK

Share Price

GBX62.50

Change (1 day)

+0.00%

52-Week Range

GBX43.50 - GBX92.50

All Time High

GBX450.00